HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Biochemistry

• Publication date

  2010-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.clinbiochem.2009.12.016PMID 20026098
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HER2/neu (c‐erbB‐2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens

  2009cited by this paper
• Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells

  2009cited by this paper
• HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis

  2009cited by this paper
• Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.

  2009cited by this paper
• Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.

  2009cited by this paper
• The biological properties of cetuximab.

  2008cited by this paper
• A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.

  2008cited by this paper
• Measurement of mRNA of 11 biomarkers by RT-PCR to detect lymph node involvement in cervical cancer.

  2008cited by this paper
• Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.

  2007influential reference
• Regulation of MAPKs by growth factors and receptor tyrosine kinases.

  2007cited by this paper
• The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma.

  2007cited by this paper
• Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers

  2007cited by this paper
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• HER-2 codon 655 polymorphism in cervical carcinogenesis

  2005cited by this paper
• Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

  2005cited by this paper
• Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case–control study

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• HER2 expression in cervical cancer as a potential therapeutic target

  2004cited by this paper
• Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix

  2004cited by this paper
• Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women.

  2004cited by this paper
• Molecular and functional characteristics of erbB2 in normal and cancer breast cells.

  2004cited by this paper
• The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk

  2004cited by this paper
• HER2 Codon 655 Polymorphism and Risk of Breast Cancer in African Americans and Whites

  2003cited by this paper
• Epidemiologic classification of human papillomavirus types associated with cervical cancer.

  2003cited by this paper
• The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years.

  2003cited by this paper
• Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy

  2003influential reference
• Prognostic significance of c‐erbB‐2/HER2 expression in advanced uterine cervical carcinoma with para‐aortic lymph node metastasis treated with radiation therapy

  2003cited by this paper
• The HER2 I655V Polymorphism and Breast Cancer Risk in Ashkenazim

  2003cited by this paper
• Regulation of the Metastatic Process by E‐Selectin and Stress‐Activated Protein Kinase‐2/p38

  2002cited by this paper
• A putative molecular-activation switch in the transmembrane domain of erbB2

  2002influential reference
• The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

  2001cited by this paper
• Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States.

  2001cited by this paper
• Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

  2000cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase

  1999cited by this paper
• c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease.

  1995cited by this paper
• ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix.

  1994cited by this paper
• Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.

  1994cited by this paper
• G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene.

  1991cited by this paper
• A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization.

  1990cited by this paper
• Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

  1989cited by this paper
• Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene

  1988cited by this paper
• Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

  1986cited by this paper
• A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

  1985cited by this paper

• HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.

  2021cites this paper
• HER2Ile655Val Polymorphism and Risk of Breast Cancer

  2021cites this paper
• GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA

  2020cites this paper
• ГЕНЕТИЧЕСКИЙ ПОЛИМОРФИЗМ ЗАБРЮШИННЫХ МИКСОИДНЫХ ЛИПОСАРКОМ

  2020cites this paper
• Cervical cancer in pregnancy: Analysis of the literature and innovative approaches

  2019cites this paper
• The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population

  2019influential citation
• Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice?

  2017cites this paper
• Role of HER-2 Ile655Val Polymorphism as Universal Cancer Susceptibility Marker among Different Cancers.

  2016cites this paper
• Association of HER2 codon 655 polymorphism with ovarian cancer

  2016cites this paper
• BRCA1, BRCA2, HER2 and RAD51 gene polymorphisms in breast cancer patients of Bangladesh

  2015cites this paper
• Analysis of different HER‐2 mutations in breast cancer progression and drug resistance

  2015cites this paper
• Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients

  2015cites this paper
• Lessons and implications from association studies and post-GWAS analyses of cervical cancer.

  2015cites this paper
• Genetic variants and risk of cervical cancer: epidemiological evidence, meta‐analysis and research review

  2014cites this paper
• HER 1 R 497 K and HER 2 I 655 V polymorphisms are linked to development of breast cancer

  2014cites this paper
• Analysis of the polymorphisms EGFR-r521K and ERBB2-I655V in Mexican patients with gastric cancer and premalignant gastric lesions.

  2013cites this paper
• HER1 R497K and HER2 I655V Polymorphisms Are Linked to Development of Breast Cancer

  2013cites this paper
• ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers

  2012cites this paper
• Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective

  2011cites this paper